Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists

Drug Metabolism and Disposition

Volumn 39, Issue 9, 2011, Pages 1589-1596

  Mitra, Pallabi ^a   Venitz, Jürgen ^a   Yuan, Yunyun ^a   Zhang, Yan ^a   Gerk, Phillip M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA [(3' ISOQUINOLYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' PYRIDYL)ACETAMIDO]MORPHINAN; GLYCOPROTEIN P; MU OPIATE RECEPTOR ANTAGONIST; NALTREXONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING; DRUG CLEARANCE; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG OXIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; NONHUMAN; PRIORITY JOURNAL;

ABSORPTION; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CACO-2 CELLS; CELL LINE, TUMOR; GLUCURONIDES; HUMANS; INTESTINAL ABSORPTION; METABOLIC DETOXICATION, PHASE I; MICROSOMES, LIVER; MORPHINANS; NALTREXONE; NARCOTIC ANTAGONISTS; P-GLYCOPROTEIN; PROTEIN BINDING; RECEPTORS, OPIOID, MU;

EID: 80051995849     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.038588     Document Type: Article

References (35)

1. Bidlack JM and Mathews J.L. (2009) The chemistry and pharmacology of μ- Opioid receptors, in Opiate Receptors and Antagonists - From Bench to Clinic (Dean R, Bilsky EJ, and Negus SS eds) pp 83-97, Humana Press, New York.
2. Breyer-Pfaff U and Nill K. (2004) Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J Pharm Pharmacol 56:1601-1606. (Pubitemid 39602003)
3. Caraco Y., Tateishi T., Guengerich FP, and Wood A.J. (1996) Microsomal codeine N- Demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab Dispos 24:761-764. (Pubitemid 26244218)
4. Copeland R.A. (2000) Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, John Wiley & Sons, New York.
5. Englund G., Rorsman F., Rönnblom A., Karlbom U., Lazorova L., Gråsjö J., Kindmark A, and Artursson P. (2006) Regional levels of drug transporters along the human intestinal tract: co- Expression of ABC And SLC transporters and comparison with Caco- Expression of ABC and SLC transporters and comparison with Caco And SLCTransporters in human intestinal cells: comparison between human segments and Caco2 cells. Eur J Pharm Sci 29:269-277.
6. Evers R., Kool M., Smith A.J., Van Deemter L., De Haas M, and Borst P. (2000) Inhibitory effect of the reversal agents V- 104, GF120918 and Pluronic L61 on MDR1 Pgp- 104, GF120918 and Pluronic L61 on MDR1 Pgp, MRP1- 104, GF120918 and Pluronic L61 on MDR1 Pgp, MRP1And MRP2- 104, GF120918 and Pluronic L61 on MDR1 Pgp, MRP1And MRP2Mediated transport. Br J Cancer 83:366-374.
7. Fishman J., Roffwarg H, and Hellman L. (1973) Disposition of naloxone- 7,8,3H in normal and narcotic- 7,8,3H in normal and narcoticDependent men. J Pharmacol Exp Ther 187:575-580.
8. Ghirmai S., Azar MR, and Cashman J.R. (2009) Synthesis and pharmacological evaluation of 6- Naltrexamine analogs for alcohol cessation. Bioorg Med Chem 17:6671-6681.
9. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
10. 1-acid glycoprotein and serum albumin. Drug Metab Dispos 37:1572-1575.
11. Hochman J. (2006) Role of mechanistic transport studies in lead optimization, in Optimizing the Drug-Like Properties of Leads in Drug Discovery (Borchardt Kerns EH, Hageman MJ, Thakker DR, and Stevens JL eds) pp 26-48, Springer, New York.
12. Inokuchi H., Takei T., Aikawa K, and Shimizu M. (2009) The effect of hyperosmosis on paracellular permeability in Caco- GlycoproteinMediated attenuation of absorptive transport: asymmetric effect of PGlycoprotein on absorptive and secretory transport across Caco2 cell monolayers. Biosci Biotechnol Biochem 73:328-334.
13. Kanaan M., Daali Y., Dayer P, and Desmeules J. (2009) P- Glycoprotein is not involved in the differential oral potency of naloxone and naltrexone. Fundam Clin Pharmacol 23:543-548.
14. Kobayashi K., Yamamoto T., Chiba K., Tani M., Shimada N., Ishizaki T, and Kuroiwa Y. (1998) Human buprenorphine N- Dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26:818-821. (Pubitemid 28376443)
15. Lakhani N., Sparreboom A., Venitz J., Dahut WL, and Figg W.D. (2006) Plasma protein binding of the investigational anticancer agent 2- Methoxyestradiol. Anticancer Drugs 17:977-983. (Pubitemid 44350617)
16. Le Merrer J., Becker J.A., Befort K, and Kieffer B.L. (2009) Reward processing by the opioid system in the brain. Physiol Rev 89:1379-1412.
17. Lexi-Comp (2011) Gentamicin, Lexi-Comp Online, Hudson, OH.
18. Li G., Aschenbach L.C., Chen J., Cassidy M.P., Stevens D.L., Gabra B.H., Selley D.E., Dewey W.L., Westkaemper RB, and Zhang Y. (2009) Design, synthesis, and biological evaluation of 6α- And 6β-N- And 6βNHeterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. J Med Chem 52:1416-1427.
19. Lötsch J. (2005) Opioid metabolites. J Pain Symptom Manage 29:S10-S24.
20. Maliepaard M., Scheffer G.L., Faneyte I.F., Van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., Van De Vijver M.J., Scheper RJ, and Schellens J.H. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464. (Pubitemid 32695041)
21. Matsson P., Pedersen J.M., Norinder U., Bergström CA, and Artursson P. (2009) Identification of novel specific and general inhibitors of the three major human ATP- Binding cassette transporters P- Binding cassette transporters PGp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816-1831.
22. McEnvoy G.K. (1999) AHFS Drug Information. American Society of Health-System Pharmacists, Inc., Bethesda, MD.
23. Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A, and Sugiyama Y. (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324. (Pubitemid 32896581)
24. Porter S.J., Somogyi AA, and White J.M. (2000) Kinetics and inhibition of the formation of 6β- Naltrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol 50:465-471.
25. Projean D., Morin P.E., Tu TM, and Ducharme J. (2003) Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N- Demethylation in human liver microsomes. Xenobiotica 33:841-854. (Pubitemid 37129907)
26. Seithel A., Karlsson J., Hilgendorf C., Björquist A, and Ungell A.L. (2006) Variability in mRNA expression of ABC- and SLC- And SLCTransporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 28:291-299. (Pubitemid 44218740)
27. Tong Z., Chandrasekaran A., Li H., Rotshteyn Y., Erve J.C., Demaio W., Talaat R., Hultin T, and Scatina J. (2010) In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone. Drug Metab Dispos 38:801-807.
28. Troutman MD and Thakker D.R. (2003) Efflux ratio cannot assess P-glycoprotein- GlycoproteinMediated attenuation of absorptive transport: asymmetric effect of P- GlycoproteinMediated attenuation of absorptive transport: asymmetric effect of PGlycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res 20:1200-1209. (Pubitemid 36951845)
29. Venkatakrishnan K., Von Moltke LL, and Greenblatt D.J. (1998) Human cytochromes P450 mediating phenacetin O- Deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharm Sci 87:1502-1507.
30. Ventura R., De la Torre R, and Segura J. (1988) Analysis of naltrexone urinary metabolites. J Pharm Biomed Anal 6:887-893.
31. Wall M.E., Brine DR, and Perez-Reyes M. (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 9:369-375. (Pubitemid 11057598)
32. Walsky RL and Obach R.S. (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660. (Pubitemid 38668158)
33. Weinstein S.H., Pfeffer M, and Schor J.M. (1973) Metabolism and pharmacokinetics of naloxone. Adv Biochem Psychopharmacol 8:525-535.
34. Yazdanian M., Glynn S.L., Wright JL, and Hawi A. (1998) Correlating partitioning and caco- 2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res 15:1490-1494. (Pubitemid 28427942)
35. Young A.M., Audus K.L., Proudfoot J, and Yazdanian M. (2006) Tetrazole compounds: the effect of structure and pH on Caco- 2 cell permeability. J Pharm Sci 95:717-725.